EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access

Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension

John M Flack, Michel Azizi, Jenifer M Brown, Jamie P Dwyer, Jakub Fronczek, Erika S W Jones, Daniel S Olsson, Shira Perl, Hirotaka Shibata, Ji-Guang Wang, Ulrica Wilderäng, Janet Wittes iD und 2 weitere

New England Journal of Medicine · 09.10.2025 · 393 (14) · 1363-1374

DOI: 10.1056/nejmoa2507109 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 09.10.2025. Verfasst von John M Flack und 13 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Medicine and Population Science and Policy, Division of General Internal Medicine, Hypertension Section, Southern Illinois University,…. Hauptthemen laut MEDLINE: Antihypertensive Agents, Cytochrome P-450 CYP11B2, Hypertension. Die Arbeit wurde bisher 190-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Department of Health, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antihypertensive AgentsCytochrome P-450 CYP11B2HypertensionAdultAgedFemaleHumansMaleMiddle AgedBlood PressureDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationAldosteroneTreatment OutcomeBlood Pressure Determination

Substanzen

Antihypertensive AgentsCytochrome P-450 CYP11B2Aldosterone

Autor:innen und Institutionen

  • Departments of Medicine and Population Science and Policy, Division of General Internal Medicine, Hypertension Section, Southern Illinois University, Springfield.
  • Université Paris Cité, INSERM Centre d'Investigation Clinique 1418, Paris.
  • Assistance Publique-Hôpitaux de Paris, Department of Hypertension, Hôpital Européen Georges Pompidou, Paris.
  • Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston.
  • Division of Nephrology and Hypertension, University of Utah, Salt Lake City.
  • Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Warsaw, Poland.

ORCID-Profile: Janet Wittes, Bryan Williams

Förderung

  • Department of Health
  • AstraZeneca

Zitieren

APA

Flack, J. M., Azizi, M., Brown, J. M., Dwyer, J. P., Fronczek, J., Jones, E. S. W., Olsson, D. S., Perl, S., Shibata, H., Wang, J. G., Wilderäng, U., Wittes, J., Williams, B., & BaxHTN Investigators (2025). Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. New England Journal of Medicine, 393(14), 1363-1374. https://doi.org/10.1056/nejmoa2507109

Vancouver

Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. New England Journal of Medicine. 2025;393(14):1363-1374. doi:10.1056/nejmoa2507109

BibTeX
@article{Flack2025,
  author = {Flack, John M and Azizi, Michel and Brown, Jenifer M and Dwyer, Jamie P and Fronczek, Jakub and Jones, Erika S W and Olsson, Daniel S and Perl, Shira and Shibata, Hirotaka and Wang, Ji-Guang and Wilderäng, Ulrica and Wittes, Janet and Williams, Bryan and BaxHTN Investigators, BaxHTN Investigators},
  title = {Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {14},
  pages = {1363--1374},
  doi = {10.1056/nejmoa2507109}
}
Kostenlos starten →